Latest Breaking News On - Institutional investors weigh in on apellis pharmaceuticals - Page 1 : comparemela.com

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Receives $76 67 Consensus Price Target from Analysts

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Receives $76 67 Consensus Price Target from Analysts
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesRobertw bairdCedric francoisPascal deschateletsInstitutional investors weigh in on apellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyApellis pharmaceuticalsAnalyst recommendations for apellis pharmaceuticalsFirst horizon advisors incApellis pharmaceuticals price performanceApellis pharmaceuticals company profileInsider transactions at apellis pharmaceuticalsSecurities exchange commissionApellis pharmaceuticals incNeedham companyFinancial wealth managment

Short Interest in Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Expands By 16 1%

Short Interest in Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Expands By 16 1%
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesTimothy eugene sullivanA sinclair dunlopFirst horizon advisors incNews ratings for apellis pharmaceuticals dailyNeedham companySecurities exchange commissionInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticals incApellis pharmaceuticalsJefferies financial groupApellis pharmaceuticals price performanceFinancial wealth managmentGet free reportEugene sullivanExchange commission

Needham & Company LLC Reiterates Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS)

Needham & Company LLC Reiterates Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Adamj townsendDavido watsonJennison associatesApellis pharmaceuticals stock downApellis pharmaceuticalsApellis pharmaceuticals incNeedham companyPricet rowe associates incNews ratings for apellis pharmaceuticals dailyAnalyst recommendations for apellis pharmaceuticalsPolar capital holdings plcInstitutional investors weigh in on apellis pharmaceuticalsNorges bankJefferies financial groupFree reportFinancial group

Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC

Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Raymond jamesZurcher kantonalbank zurich cantonalbankNur nicholsonAdamj townsendApellis pharmaceuticals incFirst horizon advisors incApellis pharmaceuticals company profileApellis pharmaceuticals stock performanceAnalyst recommendations for apellis pharmaceuticalsGoldman sachs groupApellis pharmaceuticalsAssetmark incJpmorgan chase coNeedham companyYork mellon corpSecurities exchange commission

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48 81

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48 81
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United kingdomPascal deschateletsRaymond jamesAdamj townsendZurcher kantonalbank zurich cantonalbankApellis pharmaceuticals stock performanceFirst horizon advisors incCambridge trust coCommonwealth equity servicesNews ratings for apellis pharmaceuticals dailyInstitutional investors weigh in on apellis pharmaceuticalsSecurities exchange commissionJpmorgan chase coApellis pharmaceuticalsApellis pharmaceuticals incYork mellon corp